Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery.

N Engl J Med

Department of Obstetrics, Gynecology and Reproductive Science, Mount Sinai School of Medicine, New York, NY 10029-6574.

Published: September 1991

Background: Preterm delivery is the leading cause of neonatal mortality in the United States, but efforts to address the problem are hampered by the inability to predict accurately which pregnancies are at risk. We postulated that damage to the fetal membranes may release fetal fibronectin into the cervix and vagina, giving rise to a biochemical marker for preterm delivery.

Methods: We measured fetal-fibronectin concentrations in cervical and vaginal secretions, amniotic fluid, and maternal plasma with a sensitive immunoassay using the monoclonal antibody FDC-6. Immunohistochemical studies were used to determine the distribution of fetal fibronectin in the placenta and amniochorionic membranes and to ascertain its cell of origin.

Results: Women with uncomplicated pregnancies (n = 163) who delivered at term rarely had cervicovaginal fetal-fibronectin concentrations above 0.05 micrograms per milliliter between 21 and 37 weeks of gestation (11 of 267 cervical samples [4 percent] and 9 of 267 vaginal samples [3 percent]. High levels of fetal fibronectin were detected in amniotic fluid and in the cervical or vaginal secretions of 93.8 percent of the women with preterm rupture of membranes (n = 65). Cervical or vaginal fetal fibronectin was also present in 50.4 percent of the women with preterm uterine contractions and intact membranes (n = 117), and its presence identified the women who delivered before term (n = 60) with a sensitivity of 81.7 percent and a specificity of 82.5 percent. In the placenta and membranes, fetal fibronectin was found at points of contact with the uterine wall.

Conclusions: The presence of cervicovaginal fetal fibronectin in the second and third trimesters of pregnancy identifies a subgroup of women who are at high risk for preterm delivery. This phenomenon may reflect the separation of the chorion from the decidual layer of the uterus, with the release of intact or degraded chorionic components of the extracellular matrix into the cervical and vaginal secretions.

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJM199109053251001DOI Listing

Publication Analysis

Top Keywords

fetal fibronectin
28
cervical vaginal
20
vaginal secretions
16
preterm delivery
12
fetal
8
fetal-fibronectin concentrations
8
amniotic fluid
8
delivered term
8
samples percent]
8
percent women
8

Similar Publications

Background: Preeclampsia is a common condition associated with significant maternal and foetal complications. The diagnosis of preeclampsia is based on clinical criteria, with recent introduction of angiogenic markers as an aid to clinical triage. Several biomarkers are now available in a point-of-care test format, which provide swift results to support clinical decision-making.

View Article and Find Full Text PDF

Objectives: To evaluate glycosylated fibronectin (GlyFn) as a novel biomarker for preeclampsia and preeclampsia-related complications, and to compare GlyFn to traditional biomarkers, including soluble Fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF).

Study Design: Secondary analysis of a prospective cohort study (n = 524) with suspected preeclampsia (control), gestational hypertension (GH), or confirmed preeclampsia/hemolysis, elevated liver enzymes and low platelets syndrome (PE/HELLP).

Main Outcome Measures: GlyFn levels in PE/HELLP versus control and GH.

View Article and Find Full Text PDF
Article Synopsis
  • Breast cancer is the leading cause of cancer-related deaths among women globally, with metastasis being a key factor in these fatalities.
  • The study investigates the role of the TEA domain transcription factor 4 (TEAD4) in promoting tumor cell adhesion and migration through the regulation of the adhesion molecule Fibronectin (FN1), highlighting its potential links to cancer metastasis.
  • Curcumin is shown to reduce the migration and invasion abilities of breast cancer cells by inhibiting TEAD4's interaction with the FN1 promoter, suggesting that targeting the TEAD4-FN1 axis could help mitigate breast cancer metastasis.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!